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Background: Hepatic resection is the preferred treatment for huge hepatocellular carcinoma (>10 cm in diameter;
H-HCC). However, the patients with H-HCC suffer from poor prognosis due to the early recurrence/metastasis. The
underlying mechanism of H-HCC’s early recurrence/metastasis is currently not well understood.
Results: Here, we describe an Isobaric Tags for relative and absolute quantification (iTRAQ)-based quantitative
proteomics approach to analyze the early recurrence/metastasis related proteins of H-HCC after radical resection
through multidimensional chromatography coupled with tandem mass spectrometry (2DLC-MS/MS). The different
protein expression profiles between the early recurrence/metastasis within 6 months(R/M≤6months) and late
recurrence/metastasis within 6–12 months after surgery (R/M6-12months) were confirmed and might reveal different
underlying molecular mechanisms. We identified 44 and 49 significantly differentially expressed proteins in the
R/M≤6months group and the R/M6-12months group compared to the group who had no recurrence within 2 years post
surgery (the NR/M group), respectively. Moreover, among those proteins, S100A12 and AMACR were down
regulated in the R/M≤6months group but up-regulated in the R/M6-12months group; and this regulation was further
confirmed in mRNA and protein level by Q-PCR, Western-Blot and Immunohistochemistry (IHC).
Conclusions: This current study presents the first proteomic profile of the early recurrence/metastasis of H-HCC.
The results suggest that S100A12 and AMACR might be potential prognostic markers for predicting the early
recurrence/metastasis of H-HCC after hepatectomy.
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Potential prognostic biomarkerBackground
Hepatocellular carcinoma (HCC), the fifth most com-
mon cancer worldwide [1], is reported to be the second
leading cause of cancer death in China [2]. Huge hepato-
cellular carcinoma (H-HCC) with the feature of diameter
larger than 10 cm, is a special subtype of HCC. Despite
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unless otherwise stated.H-HCC [3,4], the prognosis of H-HCC patients remains
poor, mainly due to the intra-hepatic recurrence and/or
extra-hepatic metastasis. The incidence of recurrence/
metastasis within 12 months in the residual liver of H-
HCC patients who underwent curative resection, ranges
from 50% to 70% [5-7]; and the median survival after
recurrence/metastasis is only 13 months [8]. This has
largely blocked the curative efficiency and long-term
survival of hepatectomy.
In the last two decades, various molecular alterations
have been found to correlate with early recurrence/
metastasis of HCC [9-12]. However, the detailed under-
lying molecular mechanisms of the early recurrence/Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recurrence/metastasis of HCC is a complicated process,
which is resulting from combined effects of multiple
factors [13].
Studies focusing on individual gene or protein might be
insufficient for elucidating the biological natures of the
malignant behavior of tumor. Quantitative proteomics ap-
proaches, which are able to give an overview of the global
protein profile alternation under pathological conditions,
have been proposed to be extremely useful tools in study-
ing the recurrence/metastasis behavior of cancer [14-18].
Several groups have been extensively applying the proteo-
mics approach to elucidating the biological behaviors of
HCC; Sun et al. have studied the differentially expressed
proteins in tumor and adjacent non-tumor tissue samples,
and found that Hcp70/Hsp90-organizing protein and
heterogeneous nuclear ribonucleoproteins C1/C2 could
be potential biomarkers in HCC [19]; Orimo et al. have
studied the protein expression alternations in 45 surgically
resected tissues with different degree of histological differ-
entiation, and identified APC-binding protein EB1 (EB1)
as a potential prognostic biomarker for HCC [20]. How-
ever, the traditional proteomics based approaches suffer
from low throughput non-quantitative information coupled
with difficulties in separating and/or detecting low abun-
dant proteins [21], post translationally modified proteins
[22,23], as well as those proteins with a pI value lower
than 4 or higher than 9 [24].
Recently, high-throughput quantitative proteomic tech-
niques have been developed [25-28]. In particular, isobaric
tags for relative and absolute quantification (iTRAQ)
labeling followed by nano liquid chromatography-mass
spectrometry (NanoLC-MS/MS) is an extremely effect-
ive method for simultaneous quantitative comparison
and analyzing the protein expression profile of multiple
samples. Especially, this has been useful for studying
disease associated and low abundance proteins [29-34]
with good sensitivity. So far, several groups have reported
the applying of iTRAQ based quantitative proteomics ap-
proach in the study of hepatic cancer, especially for the
screening of diagnostic or prognostic protein biomarkers.
He et al. have reported the serum biomarker screening of
AFP negative HBV related HCC through the iTRAQ
based approach [35]; Ko et al. have reported the iTRAQ
based quantitative analysis of HCC cancer stem cell prote-
ome [36]; Huang et al. have reported the iTRAQ based
serum biomarker screening of the HCC micro-vascular
invasion [37]; Qin et al., Yu et al. and Wang et al. have
reported the screening of metastatic related proteins of
HCC through iTRAQ based approach [33,38,39]; the
iTRAQ based quantitative study of proteome change
during HBV infection has also been reported [40,41].
However, the application of iTRAQ labeling in studying
the molecular mechanisms and screening for biomarkersassociated with the early recurrence/metastasis of H-HCC
has not yet been reported to our knowledge.
In the present study, we applied the iTRAQ based
quantitative proteomic approach (iTRAQ-2DLC-MS/MS)
to quantitatively analyze the protein profiles and alterna-
tions of the early recurrence/metastasis in H-HCC after
radical hepatic resection, and tried to identify the potential
prognostic markers and reveal the underlying mechanism
of the early recurrence/metastasis in H-HCC.
Results
The quantitative proteomics of the recurrence/metastasis
of H-HCC
Here, the proteins were identified and quantified accord-
ing to the following criteria: a protein is reported if a
quantification ratio was obtained using at least 2 unique
peptides with “unused” confidence cutoff (PortScore) >1.3
(95%); 1408 proteins (1818 proteins before grouping)
were identified from 23767 distinct peptides; and 1279
unique proteins were quantified from samples analyzed
on QSTAR Elite. A complete list of proteins identified
in our study is shown in Additional file 1; the details of
proteomic analysis including sequence coverage, score
of unique peptides, quantification results with percentage
variability are included in the list as well. The protein ex-
pression alternations in different groups were calculated
from the intensity ratio of the iTRAQ reporter ions from
the derived peptides. Full details of the dataset and supple-
mentary can be accessed through ftp://epigenome.fudan.
edu.cn/ by using FlashFXP.
Categorization and functional annotation of proteins
quantitated in R/M≤6months and R/M6-12months
Functional annotations of all the identified proteins
through IPA are shown in Additional file 2: Figure S1.
Categories are based on primary localization, which in-
clude nucleus (17%), extracellular space (9%), cytoplasm
(65%), plasma membrane (6%), while 3% of the identified
proteins is currently not clearly classified (Additional
file 2: Figure S1A). Moreover, molecular type of proteins
was also analyzed, of which nearly half of the identified
proteins are enzymes and transporters (Additional file 2:
Figure S1B).
At the same time, functional annotation of all the
identified proteins by Gene Ontology (GO) including
biological process, sub-cellular localization and molecu-
lar function are shown in Additional file 2: Figure S2
and the top 10 involved functions were ranked in term
of the enrichment.
In this study, we designated the differentially expressed
proteins with the fold change cutoff ratio < 0.5 or >2.0.
Figure 1A shows iTRAQ fold changes of all identified pro-
teins, and a small subset of differential expressed proteins
in both R/M≤6months and R/M6-12months group compared
Figure 1 The sub-cellular distribution and biological functional annotation of identified proteins. (A) The protein expression distributions
of R/M≤6months and R/M6-12months; the differential expressed proteins in R/M≤6months and R/M6-12months comparing to the NR/M group was
indicated by the blue tag. (B) Go analysis for biological functions of the differentially expressed proteins in R/M≤6months and R/M6-12months, the top
10 were shown in panel B. (C) KEGG pathway enrichment analysis of the differentially expressed proteins in R/M≤6months and R/M6-12months
group (p < 0.1).
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ferentially expressed proteins (15 up-regulated and 31
down-regulated) were detected in the R/M≤6months
group and 49 differentially expressed proteins (33 up-
regulated and 16 down-regulated) were detected in the
R/M6-12months group upon comparison with the NR/M
group (Additional file 1: Table S1 and Table S2). Func-
tional annotations of these differentially expressed pro-
teins (compared to the NR/M group) were analyzed as
follows: (A) Gene Ontology (GO) analysis to reveal the
different involved biological functions in R/M≤6months and
R/M6-12months (Figure 1B), (B) KEGG pathway enrichment
analysis which reveals that the drug metabolism as well
as complement and coagulation cascades were mainly
involved in R/M≤6months; metabolism related signaling
pathways (like ribosome metabolism, porphyrin and
chlorophyll metabolism) were actively involved in theR/M6-12months group (Figure 1C) and (C) GO analysis of
cell components and molecular function analysis to re-
veal the different characters of the early (R/M≤6months
group) and late (R/M6-12months group) recurrence/
metastasis patients (Additional file 2: Figure S3). All
the differentially expressed proteins in R/M≤6months
and R/M6-12months comparing to the NR/M group
have been listed in Additional file 1: Table S1 and
Table S2, respectively. Comparison of results from
Additional file 1: Table S1 and Table S2, clearly re-
veals that over 80% of the protein expression alter-
nations were different between R/M≤6months group
and R/M6-12months group. It indicates that the early
recurrence/metastasis might be induced by different
factors compared to the late stage recurrence/metastasis;
indicating that they are possibly undergoing different
molecular mechanisms.
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R/M6-12months
By carefully comparing the protein expression alterna-
tions, there are 4 types of trends according to the pro-
tein fold changes. The first type is the altered proteins
decreased in the R/M≤6months group, but increased in theFigure 2 Alternation tendency of proteins in R/M≤6months group and R
proteins which are decreased in the R/M≤6months group, but increased in th
are mostly related with glycolysis and protein synthesis. (B) The proteins w
group comparing to the NR/M group; these proteins are mostly involved in
in both R/M≤6months group and R/M6-12months group comparing to the NR/M
metabolic process. (D) The proteins which are increased in the R/M≤6month
NR/M group; these proteins are involved in multiple signaling pathways.R/M6-12months group comparing to the NR/M control
group; in these proteins, the enzymes related to the
glycolysis (ADH1B, ALDH3A1, MAOA, ALDH16A1)
and the proteins related to protein synthesis (RPL7A,
PA2G4, MCTS1, EFTUD2) were involved in (Figure 2A).
While ribosome proteins related to protein synthesis/M6-12months group comparing to the NR/M group. (A) The
e R/M6-12months group comparing to the NR/M group; these proteins
hich are highly expressed in both R/M≤6months group and R/M6-12months
protein synthesis process. (C) The proteins which are lowly expressed
group; these proteins are mostly related to the amino acid
s group, but decreased in the R/M6-12months group comparing to the
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and R/M6-12months group comparing to the NR/M
group, such as RPL7, RPL26, RPL21, RPL34, RPL7,
RPL23A etc. (Figure 2B). Figure 2C shows proteins de-
creased in both R/M≤6months group and R/M6-12months
group compared to the NR/M control group, which are
involved in the amino acid metabolic process (EARS2,
IDH1, PASN, AGXT). Lastly, there is exists another
type of differentially expressed proteins whose expres-
sion is increased in the R/M≤6months group, but decreased
in the R/M6-12months group in comparison with the NR/M
group and lying scattered in multiple signaling pathways
(Figure 2D).
By carefully comparing the protein expression alterna-
tions, we filtered 8 proteins that altered their expression in
both R/M≤6months group and R/M6-12months group relative
to the NR/M group, which might closely relate to the
metastatic propensity (Table 1). These proteins mostly
belong to the secretory proteins category (Galectin-4
and S100A12), transport proteins (Lactotransferrin and
Apo-lipoprotein A-II), transcription and translation fac-
tors (60-kDa-SS-A/Ro ribonucleoprotein and Eukaryotic
translation initiation factor 3 subunit B, eIF3b), and
antioxidant proteins (Biliverdin Reductase A and Alpha-
methy-lacyl-CoA racemase, AMACR). Although these pro-
teins have rarely been linked with cancer, the signaling
pathways regulated by these proteins and their protein
families play an important role in oncogenesis, and are
extensively involved in the invasion and metastasis of
tumor [42-49].
In these proteins, we could clearly see that the protein
S100A12 and AMACR show different alternation ten-
dency between R/M≤6months group and R/M6-12months
group; the protein S100A12, which has been reported to
regulate the calcium metabolism and arachidonic acid
metabolism in the neutrophil [50], is down regulated
more than 3.3 folds in R/M≤6months group compared to
the NR/M group, but up regulated more than 3.6 folds
in R/M6-12months group relative to the NR/M group.
AMACR, which has been reported to regulate theTable 1 List of common proteins altered their expression in b
Accession number %Cov Protein name
LEG4_HUMAN 33.1 Galectin-4
S10AC_HUMAN 27.2 Protein S100-A12
AMACR_HUMAN 42.9 Alpha-methylacyl-CoA racemase
TRFL_HUMAN 18.6 Lactotransferrin
EIF3B_HUMAN 13.1 Eukaryotic translation initiation facto
BIEA_HUMAN 17.6 Biliverdin reductase A
RO60_HUMAN 13.9 60 kDa SS-A/Ro ribonucleoprotein
APOA2_HUMAN 73 Apolipoprotein A-IImetabolism of fatty acid, cholalic acid [51] and closely
associated with the differential diagnosis of prostatic
cancer [52], was down regulated by over 2.8 folds in
R/M≤6months group compared to the NR/M group, but
up-regulated more than 2.2 folds in R/M6-12months
group compared to the NR/M group. Since these two
proteins have clearly different expression profiles in
the R/M≤6months group and the R/M6-12months group,
they might be interesting potential biomarkers for pre-
dicting early recurrence/metastasis after radical resec-
tion in H-HCC.
Functional analysis of the protein expression alternations
in the recurrence/metastasis of H-HCC
To analysis the roles of the protein expression alterna-
tions in the recurrence/metastasis of H-HCC, we used
the IPA software to study the key signaling pathways
and networks of those differentially expressed proteins.
The analyzed results suggest that different signaling
pathways are indeed involved in the early (R/M≤6months
group) and late (R/M6-12months group) recurrence/me-
tastasis patients, although there are common signaling
pathways involved in as well. The IPA software identified
that the altered protein expressions in the R/M≤6months
group patients are mostly involved in ERK1/2 signaling
pathway and TNF signaling pathway, but the altered
protein expressions in the R/M6-12months group patients
are mostly involved in TNF signaling pathway and NFκB
signaling pathway.
In the R/M≤6months group patients, we could see that
14 proteins (including 6 up-regulated proteins and 8
down-regulated proteins) were involved in the ERK1/2
signaling pathway (Figure 3A); and 13 proteins (including
4 up-regulated proteins and 9 down-regulated proteins)
involved in TNF signaling pathway (Figure 3B). In the
R/M6-12months group patients, 12 proteins (including 7
up-regulated proteins and 5 down-regulated proteins)
involved in the TNF signaling pathway (Figure 3C); and
13 proteins (including 11 up-regulated proteins and 2













Figure 3 The key signaling pathways involved in the early recurrence/metastasis (R/M≤6months) and late recurrence/metastasis
(R/M6-12months) of H-HCC. (A) The alternations of the ERK1/2 signaling pathway in the R/M≤6months group, including 6 up-regulated proteins (red
labeling) and 7 down-regulated (green labeling) proteins. (B) The alternations of the TNF signaling pathway in the R/M≤6months group, including 4
up-regulated proteins (red labeling) and 9 down-regulated proteins (green labeling). (C) The alternations of the TNF signaling pathway in the
R/M6-12months group, including 7 up-regulated proteins (red labeling) and 5 down-regulated proteins (green labeling). (D) the alternations of the
NFκB signaling pathway in the R/M6-12months group, including 9 up-regulated proteins (red labeling) and 2 down-regulated (green labeling) proteins.
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pathways are actively associated with cancers [53-55], as
describing above, only the TNF signaling pathway is ex-
tensively involved in both the early and late recurrence/
metastasis of H-HCC. The reported functions of TNF
signaling pathway in carcinogenesis include tumor initi-
ation, tumor cell proliferation, tumor angiogenesis, and
enhancing the invasive property of tumor cells [55,56];
therefore, it is not surprising that the TNF signaling
pathway is involved in both groups. Interestingly, al-
though both the ERK1/2 signaling pathway and the
NFκB signaling pathway are reported to associated with
cancer development, during malignant transformation
and metastasis [53,54], only the ERK1/2 signaling path-
way is enriched in the early (R/M≤6months) recurrence/
metastasis patients. ERK1/2 is known an extremely im-
portant regulator of cell growth and proliferation [54],
therefore, the early recurrence/metastasis H-HCC cells
probably have stronger growth and proliferation abilitiesthan late recurrence/metastasis H-HCC cells; but the
detailed underlying mechanisms should be further
studied.
The verification of S100A12 and AMACR expression
alternation
As mentioned above, the protein S100A12 and AMACR
were reversely expressed in the R/M≤6months group (early
recurrence/metastasis) and the R/M6-12months group (late
recurrence/metastasis). Therefore, they might be poten-
tial interesting biomarkers to predict the early and late
recurrence/metastasis in H-HCC. Here, we took liver
sections from H-HCC patients to verify their expression
profiles and predicting potentials in a larger scale.
Combing with the patient case history, the expression
profiles of both S100A12 and AMACR in different
groups were confirmed by Q-PCR at the mRNA level
and by Western-blot and immunohistochemistry in the
protein level.
Figure 4 Verification of differentially expressed proteins in different stage of recurrence/metastasis in huge hepatocellular carcinoma
patients. (A) The mRNA expression level of S100A12 and AMACR (p < 0.05, paired T-test); (B) The protein expression level of S100A12 and AMACR
when validated by Western-Blot (p < 0.05, paired T-test); (C) The immunohistochemistry staining results of S100A12 and AMACR (with 400x
magnification). Both S100A12 and AMACR are strongly over-expressed on the patient’s samples from R/M6-12months group, but down regulated on
the patient’s samples from R/M≤6months group when it is comparing with the control samples.
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S100A12 and AMACR were down-regulated 2.5 fold
and 14.2 fold in the R/M≤6months group (n = 20 patients),
respectively; but up-regulated 5.1 fold and 5.38 fold in
R/M6-12months group (n = 20 patients), respectively. As
shown in Figure 4B, the protein expression of S100A12
and AMACR are down regulated 1.75 fold and 16.6 fold in
the R/M≤6months group (n = 20 patients), respectively; but
up-regulated 2.14 fold and 1.38 fold in the R/M6–12 months
group (n = 20 patients), respectively. These results
thus fitted well with the quantitative proteomics study




R/M≤6months group 20 16
R/M6-12months group 20 3
NR/M group 20 9
a)P value listed above stands for the significance of the S100A12 positive expression
group respectively. P value less than 0.05 is taking as significant difference with ChTo further confirm the protein expression and loca-
lization profiles of S100A12 and AMACR, the immuno-
histochemistry was performed on patient’s liver sections.
As shown in Figure 4C, both the expression intensity
and the positive rate (Tables 2 and 3) of the S100A12
and AMACR were down regulated in the R/M≤6months
group but up regulated in the R/M6-12months group, com-
pared to the NR/M group respectively.
Combining with the patient’s case history and the ex-
pression profiles of S100A12 and AMACR, these two pro-
teins could well distinguish the early (within 6 months)
and late (from 6 to 12 months) recurrence/metastasis ofxpression level on patient’s samples with different
ion




rate when R/M≤6months group and R/M6-12months group compared with NR/M
i-square test.
Table 3 Immunohistochemistry assessment of the AMACR expression level on patient’s samples with different
recurrence/metastasis stage
AMACR expression
Groups Numbers Negative Positive Positive expression rate (%) P valuesa)
R/M≤6months group 20 17 3 15.0 0.041
R/M6-12months group 20 2 18 90.0 0.014
NR/M group 20 10 10 40.0
a)P value listed above stands for the significance of the AMACR positive expression rate when R/M≤6months group and R/M6-12months group compared with NR/M
group respectively. P value less than 0.05 is taking as significant difference with Chi-square test.
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for the predicting of early recurrence/metastasis of
H-HCC, but the underlying molecular mechanisms
needs to be further dissected.Discussions
As reported in our previous clinical studies [57], the
early recurrence/metastasis of H-HCC is affected by
multiple factors. The independent risk factors for the
early recurrence/metastasis occurred within 6 months,
and those factors for the late recurrence/metastasis are
different and occurred between or after 6 to 12 months.
Therefore, the underlying molecular mechanism of the
early (occurred within 6 months) and late (occurred from
6 months to 12 months) recurrence/metastasis might be
different.
The recent rapid development of proteomic techniques
allow a full-scale illustration of the protein expression
profile alteration under a particular disease circum-
stance, and thus in identifying important disease-related
protein biomarkers or therapeutic targets [33,35-41]. The
HCC associated proteomics is believed to further facilitate
the studies on systematic screening of the molecular
mechanisms involved in HCC recurrence/metastasis, and
in the development of prognosis biomarkers for HCC
recurrence/metastasis.
In this paper, we applied the iTRAQ based quantitative
proteomics approach to study the overall protein profile
alternations in the early and late recurrence/metastasis
of H-HCC. Here, we successfully identified 46 and 49
differentially expression proteins in the R/M≤6months
group and R/M6-12months group compared to the NR/M
group, respectively; however, we fished out only 8 pro-
teins that altered its expression in both R/M≤6months
group and R/M6-12months group. In our study, we pooled
the samples to standardize the reading since the individual
sample is likely to give highly divergent and incoherent re-
sults; while with pooled samples one could lose informa-
tion on individual patient variability and also might mess
up the readings if there are sub-groups. However, many of
the studies utilizing clinical samples face similar problems,
which to certain extent limit the development of clinical
proteomics.Among those identified proteins, over 80% of the
expression altered proteins were different between
the R/M≤6months group and R/M6-12months group, which
suggested different molecular mechanisms operate during
the early (within 6 months) and late (from 6 to 12 months)
recurrence/metastasis of H-HCC. This finding fitted well
with our initial hypothesis. Therefore, those H-HCC pa-
tients who had recurrence/metastasis at different time
points as per our classification (early or late) might need
completely different medical treatment. In such a case, it
is necessary to identify novel biomarkers and therapeutic
targets for distinguishing, predicting and treating the early
and late recurrence/metastasis, which will certainly pro-
vide important guidelines for identifying H-HCC patients
with high risk of early recurrence/metastasis.
The indentified protein expression alterations involve
several biological processes, including carbohydrate metab-
olism, lipid metabolism, cell-cell communication, apoptosis,
proliferation, anti-oxidation, transcription and translation,
which are confirming that the malignant behavior of HCC
cells is controlled by complicated signaling process. Some
of the identified proteins have also been described to be as-
sociated with HCC recurrence/metastasis. For example,
CK19 is up-regulated 2.35 folds in R/M6–12 months group
compared with NR/M group; it has been reported to be
highly expressed in HCC tissues, and the patients with
positive CK19 results had a higher incidence of pulmonary
metastasis within 1 month after receiving surgical resection
[58]. Periostin (PN) is a secreted matrix glycoprotein, which
has been reported to be closely related with the metastatic
potential and prognosis of HCC after surgery [59]; Clus-
terin has been reported to promote the HCC metastasis
via regulating TGF-β1-smad3 signaling and then induction
of the epithelial-mesenchymal transition (EMT) process
[60]. In our study, the expressions of those proteins have
also proved to be altered in the R/M6-12months group
patients. Therefore, it is clearly establishes that our quanti-
tative proteomics approach is suitable for studying the
recurrence/metastasis of H-HCC.
In our clinical, more than 50% of H-HCC patients
have recurrence/metastasis within 6 months after radical
surgery [58]. However, we did not have any techniques
or biomarkers available to early predict the recurrence/
metastasis risky of H-HCC patients so far. Predicting
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patients will improve the prognosis. In our study, we
identified that protein S100A12 and AMACR were re-
versely expressed in the early (within 6 months, down
regulated) and late (from 6 to 12 months, up regulated)
recurrence/metastasis H-HCC patients; and further val-
idated these findings from clinical samples at the level
of both mRNA and protein expression. The recurrence/
metastasis of HCC is closely related with clinical param-
eters such as the size of tumor, tumor capsule, tumor
boundaries, portal vein tumor thrombosis (PVTT), intra-
operative ascites, cirrhotic nodule, heteroploidy, PCNA
(Proliferating Cell Nuclear Antigen) expression and others.
Our study shows that the low expression of AMACR is re-
lated with the absence of tumor capsule, indistinct tumor
boundary as well as presence of portal vein tumor throm-
bosis (PVTT) and intraoperative ascites, which fits with
the earlier recurrence/metastasis of AMACR lower
expression group.
S100A12 is a new member of S100 protein family
(calcium binding protein family); the gene encoding
S100A12 was localized on the human chromosome 1q21
[61], and is normally expressed in neutrophil granulocytes,
with low expression in both lymphocytes and monocytes
[50]. Its reported function involves calcium regulation and
arachidonic acid metabolism in the neutrophile granulo-
cytes [50]; it has also been reported that the expression of
S100A12 was up-regulated both at mRNA and protein
levels in the patients with colorectal carcinoma relative
to healthy volunteers [62]. The AMACR encoding gene
is localized on chromosome 5p13 [51]; it is probably
involved in the metabolism of fatty acid and cholalic
acid [51]. Previous studies have reported the application
of AMACR in the diagnosis of prostatic cancer [62,63]
and there are also a few studies that reported AMACR
could be used as biomarker to distinguish the hepato-
cellular carcinoma and the benign tissue [64,65]. How-
ever, these two proteins were rarely reported to be
associated with the prognosis of HCC. In this study, we
not only prove that the S100A12 and AMACR were as-
sociated with the recurrence/metastasis of H-HCC, but
also clearly demonstrate that these two proteins have
completely inverse expression profiles between the early
(within 6 months, down regulated) and late (from 6 to
12 months, up regulated) recurrence/metastasis of H-HCC,
even considering a larger “n” number of clinical samples as
employed in this study. Therefore, they might be potentially
interesting biomarkers for distinguishing and predicting
the early and late recurrence/metastasis of H-HCC. How-
ever, the exact molecular mechanisms of how these two
proteins involved in the pathogenesis and progression of
H-HCC should be further verified and studied. It has been
reported that the abnormal expression of S100A12 is
closely related with inflammation and vascular invasion oftumor cell [66], over inflammation and vascular invasion
are closely related with tumor recurrence/metastasis.
Meanwhile, the low expression of AMACR was independ-
ently associated with the development of metastasis and
lethal in prostate cancer through regulating lipid metabol-
ism and nuclear receptor activity [67]. Whether or not
these reported functions are involved in the here reported
HCC recurrence/metastasis needs further studies.
Overall, we have used iTRAQ based quantitative pro-
teomics approach to study the protein expression profile
alternations of the recurrence/metastasis of Huge HCC
in different stage, and identified potentially interesting
biomarkers for early distinguishing and predicting the
recurrence/metastasis behaviors of H-HCC.
Conclusions
We have applied the iTRAQ based quantitative pro-
teomics approach to study the overall protein profile
alternations in the early (within 6 months) and late
(from 6–12 months) recurrence/metastasis of huge hepa-
tocellular carcinoma after radical resection. The results
proved different protein alternation profiles and different
signaling pathways involving in the early and late recur-
rence/metastasis of H-HCC. Meanwhile, we identified and
further verified S100A12 and AMACR might be consid-
ered as potentially interesting prognostic markers for pre-




H-HCC patients who had undergone surgery at the liver
center of the First Affiliated Hospital of Fujian Medical
University of China from April 2008 to December 2010
were evaluated for inclusion in the current study. The ab-
sence of intrahepatic recurrence/metastasis in the residual
liver was monitored by ultrasonography (US), computer
tomography (CT) scan and angiography. CT scan was also
carried out to rule out distant metastasis, including lung,
brain and bone. The H-HCC patients were monitored for
recurrence/metastasis every one month in the first year
after surgery and every 3 months after 1 year post oper-
ation, including serum AFP, US and CT scan. Enrollment
Eligibility Criteria: (1) The patient was diagnosed with
HCC by post-operative pathological examination; (2) Pre-
operative serum HBs Ag positive, but HBc Ab negative;
(3) Subject to the standard radical resection [68]: no distal
metastasis was revealed in both pre-and intra-operative
examination; no lesion was found in the rest of the liver
during intra-operative ultrasonic scan; no visible cancer
embolus in the hepatic portal vein or primary venous
branch; no cancer cell was found in the incisal margin at
the post-operative pathological examination; no recurrent/
metastatic lesion was found at the ultrasonic and CT scan
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elevated pre-operative serum AFP should decline to the
normal level after 2 months post operation; (5) The pa-
tient did not undergo any other intervention or therapies
before surgery.
The tissues of patients were divided into 3 groups ac-
cording to the time of recurrence/metastasis after oper-
ation: the patients who had recurrence/metastasis within
6 months after operation (R/M≤6Months group, n = 20);
the patients whose recurrence/metastasis occurred be-
tween 6 and 12 months after operation (R/M6-12months
group, n = 20); the patients who had no recurrence/
metastasis within 2 years of operation (NR/M group,
n = 20). Fresh tissues were collected at the time of sur-
gery from patients with HBV associated H-HCC for
liquid nitrogen preservation after washing, and part of
the tissues were formalin embedded and stored for im-
munohistochemistry. The project was approved for
the using of human biopsy by the Institution Review
Board of the First Affiliated Hospital of Fujian Medical
University. The written consent was received from all
participants in this study.
Protein preparation and iTRAQ labeling
Ten milligrams of each liver tissue were lysed in the pro-
tein extraction buffer (150 mM NaCl, 10 mM Tris, 5 mM
EDTA, 1% Triton X-100, 5% glycerol, and 0.1% SDS,
pH 7.2) after smash in liquid nitrogen, and then incubated
at 4°C for 30 min. After centrifugation at 12,000 rpm at
4°C for 30 min, the supernatant was collected, and the
protein concentration was determined according to the
BCA protocol (Beyotime, China). Samples were further
normalized based on protein concentration. The iTRAQ
labeling was performed according to the manufacturer’s
protocol (AB SCIEX, USA). Briefly, 100 μg proteins of
each group were precipitated with cold acetone for 1 hour
at −20°C, and then re-suspended in 20 μl dissolution buf-
fer. After protein reduction and alkylation followed by
overnight digestion with trypsin, the peptides were labeled
with the iTRAQ regents for 1 hour at room temperature.
The iTRAQ regents 117, 119 and 121 were used to label
the peptides from R/M≤6Months group, R/M6-12months group
and NR/M group respectively. Then the samples were
mixed with equal amounts, and desalted with the Sep-Pak
Vac C18 cartridges and dried in a vacuum centrifuge. The
workflow of our study was presented in Figure 5.
2DLC-MS/MS analysis
The mixed peptides were separated by strong cation ex-
change (SCX) chromatography using a polysulfoethanyl
column (2.1 mm × 100 mm, 5 μm, 200 Å, The Nest
Group, USA) at a flow rate of 200 μL/min for 60 min
with a gradient of 0–80% Buffer B (10 mM KH2PO4 in
25% acetonitrile, 350 mM KCl, pH 2.6) in Buffer A(10 mM KH2PO4 in 25% acetonitrile, pH 2.6) on a
20 AD HPLC system (Shimadzu, Japan), and a total of
20 SCX fractions were collected.
The mixed peptides (desalted with a PepMap C18 cart-
ridge) were further separated by nano-HPLC (20 AD,
Shimadzu, Japan) on the secondary RP analytical col-
umn (ZORBAX 300SB-C18 column, 150 mm × 100 μm,
5 μm, 300 Å, USA). Peptides were subsequently eluted
using the following gradient conditions with phase B
(95% ACN with 0.1% formic acid): 5-35% B (0–90 min),
35–80% B (90–95 min), 80–5% B (100–105 min) and
5–0% B (105-120 min); the flow rate was maintained at
300 μL/min. Electrospray voltage of 2.3 kV versus the
inlet of the mass spectrometer was used.
A hybrid quadrupole time-of-flight mass spectrometer
(QStar hybrid LC/MS/MS Q-TOF, AB SCIEX, USA) was
operated in data-dependent mode to switch automatically
between MS and MS/MS acquisition. MS spectra were
acquired across the mass range of 400–1800 m/z in
high resolution mode using 250 ms accumulation time
per spectrum. Tandem mass spectral scanned from
100–2000 m/z in high sensitivity mode with collision in-
duced dissociation (CID). The four most intense precursors
were selected for fragmentation per cycle with dynamic ex-
clusion time of 9 s.
Data analysis
The MS/MS data was searched against UniProtKB/
Swiss-Prot FASTA (it was released October 15, 2011
and consists of 20238 human sequences). Protein iden-
tification and iTRAQ quantitation were performed with
ProteinPilot software (Version 4.0, AB SCIEX, USA).
The user-defined search parameters included iTRAQ
labeling at N-terminus and lysine residues, cysteine modi-
fication by methyl methanethiosulfonate (MMTS) and di-
gestion by trypsin. For iTRAQ quantitation, the peptide
was automatically selected with the Pro Group algorithm
to calculate the reporter peak area, error factor (EF) and p
value. A decoy database search strategy was adopted to es-
timate the FDR for peptide identification. In our study, a
strict unused confidence cutoff >1.3 was used for protein
identification; proteins with at least two peptides (confi-
dence >95%) were used for quantification. The results
were then exported into Microsoft Excel for manual data
interpretation. The proteins were considered to be differ-
entially expressed if their iTRAQ ratios were >2 or <0.5 in
the R/M≤6Months group and R/M6-12months group relative to
the NR/M group (P < 0.05) [69].
Functional analysis
The biological function of all the identified proteins was
analyzed in the online Gene Ontology (GO) Term map-
per tool (http://go.princeton.edu/cgi-bin/GOTermMapper).
The function and pathway annotations of identified
Figure 5 Outline of the iTRAQ based quantitative proteomic strategy. iTRAQ labeling was carried out by using tumor tissues from the
patients who had recurrence/metastasis within 6 months after operation (R/M≤6months group, n = 20); the patients whose recurrence/metastasis
occurred between 6 and 12 months after operation (R/M6-12months group, n = 20); and the patients who had no recurrence/metastasis within
2 years of operation (NR/M group, n = 20). Samples were digested by trypsin, and the peptides from R/M≤6months, R/M6-12months, and NR/M were
labeled by iTRAQ reagents 117, 119 and 121, respectively. After labeling, peptides from all three samples were combined and fractionated by SCX
chromatography. Each fraction was then analyzed by LC-MS/MS on a QSTAR Elite mass spectrometers. The identified potential interesting targets
were further validated by Q-PCR, Western bolt and immunohistochemistry (IHC).
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(IPA) software (version 7.5), which is based on the
Ingenuity Pathways database. The involved signaling
pathways and networks were ranked in term of the
enrichment of the differentially expressed proteins.
Immunoblotting
The tissue samples from patients were further taking
for immunoblotting. The tissue samples were lysed in
extraction buffer (150 mM NaCl, 10 mM Tris, 5 mM
EDTA, 1% Triton X-100, 5% glycerol, and 0.1% SDS,
pH 7.2), then were centrifuged at 22,000 rpm, 4°C for
30 min. The supernatants were collected, and the pro-
tein concentration was determined according to BCA
protocol. Equal amount of proteins from each patient
were applied for the immunoblotting experiments. 40 μg
proteins per patients were analyzed on 12.5% SDS-PAGE,and transferred on PVDF membrane (transfer buffer:
25 mM Tris, 192 mM glycine, 20% methanol, pH8.3)
by the Bio-Rad Semidry apparatus with a constant
current of 300 mA for 1 hour or 30 min according to
the size of the protein. Afterwards, the membrane was
blocked in blocking buffer (1 × PBS, 0.5% Tween-20
with 5% nonfat milk) for 2 hours, and then further
blotted with the primary antibody (monoclonal anti-
S100A12 antibody, 1:500 dilution, Abcam; monoclonal
anti-AMACR antibody, 1:1000 dilution, Abcam; mono-
clonal anti-β-actin antibody, 1:1000 dilution, Santa Cruz)
in 4°C overnight and HRP conjugated secondary antibody
in room temperature for 2 hrs. Afterwards, the membrane
was incubated with Chemi-luminescent Detection Reagent
(Pierce) for 5 min, and then was exposed to X-ray film. All
of the above mentioned experiments were independently
repeated 3 times.
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The expression profile of the protein S100A12 and
AMACR in liver section of the patients was investigated
by the two-step Envision™ plus staining technique. The
paraffin-embedded liver sections were de-waxed and re-
hydrated through incubating in EDTA (1 mM) solution
with 3 minutes for high-pressure antigen retrieval. After-
wards, the liver section was incubated with the primary
antibody (mouse monoclonal anti-human S100A12 anti-
body, 1:500 dilution, Abcam; mouse monoclonal anti-
human AMACR antibody, 1:1000 dilution, Abcam) at 4°C
overnight, and then washed by PBS buffer for 3 times
(5 min of each) at room temperature. It further followed
by incubating with HRP-conjugated secondary antibodies
(Fuzhou Maxim Biotech Inc, China) at room temperature
for another 1 hour. Finally, the liver sections were sub-
jected to DAB coloration and hematoxylin re-staining.
The results were independently assessed by two patholo-
gists double-blindly.Q-PCR analysis
Trizol homogenization buffer (Takara Inc.) was added
into the tissue samples to extract the total RNAs, which
were then reversely transcribed into cDNAs (Reverse
transcription was conducted according to the manufac-
ture’s protocol from Takara). The β-actin was taken as
the internal reference gene. The obtained cDNAs were
used as the template for the Q-PCR analysis of the
S100A12 and AMACR genes in a total reaction system
of 50 μL (including 1 μL of the cDNA template, 1 μL of
the upstream primer, 1 μL of the down stream primer,
25 μL of the SYBR green super mix and 22 μL of the
RNase free dH2O). The reaction conditions were as
follows: 94°C, 3 min, 1 cycle; followed by 40 cycles of
95°C 15 s, 62°C 15 s (S100A12) or 60°C 15 s (AMACR),
60°C 40 s. The relative fluorescence intensity from 55°C
to 95°C (0.5°C increments every 10 sec) was collected to
plot the melting curve, so as to survey the formation of
primer dimmers and the non-specific amplification. The
relative gene expression was calculated according to the
Livak method (2-ΔΔCt). The experiments were repeated
3 times independently. The sequence information of the
primers was as follows:
S100A12, forward primer 5′-ATTAGGCTGGGAAGAT
GACAAA-3′, and the reverse primer 5′-GCTTCAGCT
CACCCTTAGAGAG-3′;
AMACR, forward primer 5′-ATTTGGCTTTGTCAGG
TGTTCT-3′, and the reverse primer 5′- GCGGTCAA
AAAGAGCCATTAT-3′;
β-actin, forward primer 5′-
CCACTGGCATCGTGATGGAC-3′, and the reverse
primer 5′- GCGGATGTCCACGTCACACT-3′.Additional files
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